Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Holders of 5% or more of PASG
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Passage BIO, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 13D | 21.00%673.8K shares | +1.40 ppfrom 19.60% | Sep 29, 20228 filings | Jul 2, 2026 | SEC |
| Baselake Partners, LP | 13G | 7.30%235.1K shares | New | Jun 25, 20261 filing | Jun 25, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
40 Schedule 13D and 13G filings on Passage BIO, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20264:05 PM ET | Vestal Point Capital, LPand 1 other | 13G/A | 0.00%0 shares | –Below 5% | Jun 30, 2026 | SEC |
| Jul 2, 20269:19 PM ET | Lynx1 Capital Management LPand 1 other | 13D | 21.00%673.8K shares | +1.40 ppfrom 19.60% | Jun 25, 2026 | SEC |
| Jun 25, 20266:44 PM ET | Baselake Partners, LPand 2 others | 13G | 7.30%235.1K shares | New | Jun 18, 2026 | SEC |
| Nov 14, 20252:01 PM ET | Lynx1 Capital Management LPand 1 other | 13G/A | 19.60%623.7K shares | +4.60 ppfrom 15.00% | Sep 30, 2025 | SEC |
| Jul 24, 20255:44 PM ET | OrbiMed Advisors LLCand 1 other | 13D/A | 4.25%132.5K shares | −3.57 ppfrom 7.82%Below 5% | Jul 22, 2025 | SEC |
| Jul 21, 20255:28 PM ET | OrbiMed Advisors LLCand 1 other | 13D/A | 7.82%243.9K shares | −1.68 ppfrom 9.50% | Jul 17, 2025 | SEC |
| Jul 9, 20258:06 PM ET | OrbiMed Advisors LLCand 1 other | 13D/A | 9.50%5.92M shares | −1.20 ppfrom 10.70% | Jul 7, 2025 | SEC |
| Apr 25, 20257:48 PM ET | OrbiMed Advisors LLCand 1 other | 13D/A | 10.70%6.65M shares | −1.30 ppfrom 12.00% | Apr 22, 2025 | SEC |
| Feb 14, 20259:01 AM ET | Lynx1 Capital Management LPand 1 other | 13G/A | 15.00%9.26M shares | – | Dec 31, 2024 | SEC |
| Dec 26, 20244:31 PM ET | OrbiMed Advisors LLCand 2 others | 13D/A | 12.00%7.40M shares | – | Dec 20, 2024 | SEC |
| Nov 14, 20245:21 PM ET | Erste Asset Management GmbH | 13G/A | 4.42%2.46M shares | −0.98 ppfrom 5.40%Below 5% | Mar 31, 2024 | SEC |
| Nov 14, 20245:01 PM ET | Erste Asset Management GmbH | 13G | 5.40%2.96M shares | New | Dec 31, 2023 | SEC |
| Nov 14, 2024 | Vestal Point Capital, LP | 13GOld format | – | New | – | SEC |
| Aug 9, 2024 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Aug 9, 2024 | Lynx1 Capital Management LP | 13G/AOld format | – | – | – | SEC |
| May 29, 2024 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Apr 12, 2024 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Mar 29, 2024 | Lynx1 Capital Management LP | 13GOld format | – | – | – | SEC |
| Feb 14, 2024 | Lynx1 Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Nov 9, 2023 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Jun 29, 2023 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Jun 15, 2023 | Frazier Life Sciences IX, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Deep Track Capital, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Lynx1 Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Sep 29, 2022 | Lynx1 Capital Management LP | 13GOld format | – | New | – | SEC |
| Aug 15, 2022 | Frazier Life Sciences IX, L.P. | 13D/AOld format | – | – | – | SEC |
| Jul 8, 20224:56 PM ET | BlackRock Inc. | 13GOld format | – | – | – | SEC |
| May 5, 2022 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Access Industries Holdings LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Deep Track Capital, LP | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | LAV Prescience Ltd | 13G/AOld format | – | – | – | SEC |
| Feb 4, 20224:12 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Dec 10, 2021 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Oct 25, 2021 | Deep Track Capital, LP | 13GOld format | – | New | – | SEC |
| Feb 12, 2021 | Vivo Capital VIII, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | New Leaf Ventures III, L.P. | 13GOld format | – | New | – | SEC |
| Feb 9, 2021 | LAV Prescience Ltd | 13GOld format | – | New | – | SEC |
| Feb 8, 2021 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Jan 28, 2021 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Jan 27, 2021 | Frazier Life Sciences IX, L.P. | 13D/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
11 notices from officers, directors and other affiliates planning to sell Passage BIO, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Jan 9, 20264:03 PM ET | Chou WilliamOfficer | 4.08K | $75.1K | Jan 9, 2026 | Maxim Group | SEC |
| Jul 21, 20255:33 PM ET | OrbiMed Private Investments VII, LPShareholder | 132.6K | $737.5K | Jul 21, 2025 | Themis Trading LLC | SEC |
| Jul 15, 20258:17 PM ET | OrbiMed Private Investments VII, LPShareholder | 53.3K | $361.9K | Jul 15, 2025 | Themis Trading LLC | SEC |
| Jul 7, 20256:02 PM ET | OrbiMed Private Investments VII, LPShareholder | 259.0K | $112.1K | Jul 7, 2025 | Themis Trading LLC | SEC |
| Jun 24, 20256:48 PM ET | OrbiMed Private Investments VII, LPShareholder | 1.08M | $378.4K | Jun 24, 2025 | Themis Trading LLC | SEC |
| Apr 15, 20255:40 PM ET | OrbiMed Private Investments VII, LPShareholder | 787.2K | $301.5K | Apr 15, 2025 | International Strategy & Investment Group LLC | SEC |
| Jan 6, 20254:57 PM ET | OrbiMed Private Investments VII, LPShareholder | 1.14M | $945.7K | Jan 6, 2025 | Themis Trading LLC | SEC |
| Dec 4, 20247:03 PM ET | OrbiMed Private Investments VII, LPShareholder | 2.99M | $2.66M | Dec 4, 2024 | Themis Trading LLC | SEC |
| Dec 4, 20246:57 PM ET | Worldwide Healthcare Trust PLCShareholder | 2.03M | $1.81M | Dec 4, 2024 | Themis Trading LLC | SEC |
| Sep 16, 20248:38 PM ET | Worldwide Healthcare Trust PLCOwner | 241.3K | $194.8K | Sep 16, 2024 | Themis Trading LLC | SEC |
| Sep 16, 20248:36 PM ET | OrbiMed Private Investments VII, LPOwner | 927.6K | $748.6K | Sep 16, 2024 | Themis Trading LLC | SEC |